Candida albicans topoisomerase II, encoded by the TOP2 gene, mediates chromosome segregation by a double-strand DNA break mechanism and is a potential target for anti-fungal therapy. In this paper, we report the characterization of the C. albicans TOP2 gene and its use to develop a yeast system that allows the identification and study of anti-fungal topoisomerase II inhibitors in i o. The gene, specifying a 1461-residue polypeptide with only 40 % identity with human topoisomerase IIα and β isoforms, was isolated from C. albicans on a 6n3 kb EcoRI fragment that mapped to chromosome 4. It was used to construct a plasmid in which TOP2 expresses a recombinant enzyme (residues 57-1461 of C. albicans topoisomerase II fused to the first five residues of Saccharomyces cere isiae topoisomerase II) under the control of a galactose-inducible promoter. The plasmid rescued the lethal phenotype of a temperature-sensitive S. cere isiae DNA topoisomerase II mutant allowing growth at 35 mC. Yeast cells,
INTRODUCTION
Candida albicans is an opportunistic fungal pathogen that causes life-threatening invasive disease in immunocompromised subjects including AIDS sufferers, those on immunosuppressive therapy for organ transplantation and patients undergoing cancer chemotherapy [1] . The organism is diploid, can exist in yeast and hyphal forms, can undergo switching among different colony morphologies, and is only distantly related to the budding yeast Saccharomyces cere isiae and the fission yeast Schizosaccharomyces pombe [2] . Unlike these yeasts, the absence of a known sexual cycle in C. albicans has slowed the application of genetic approaches. Consequently, compared with S. cere isiae, relatively little is known about its basic biology and the mechanism of action of anti-fungal agents.
Current therapies rely on two main groups of agents : amphotericin B, which disrupts membrane function, and the azoles, such as ketoconazole and fluconazole, which interfere with synthesis of ergosterol, the fungal equivalent of cholesterol needed for membrane biogenesis [3, 4] . However, the increasing prevalence of Candida infections in immunocompromised patients, dose-limiting toxicity for amphotericin B and emerging resistance to azole agents [3, 5, 6] have stimulated an interest in exploring and developing other fungal targets including DNA topoisomerases.
Studies in S. cere isiae and Sch. pombe have highlighted the essential roles of DNA topoisomerases in DNA replication and chromosome segregation. Topoisomerases alter the topological state of DNA by transiently breaking and rejoining DNA phosphodiester backbone bonds and are classified on the basis of whether they act on one DNA strand at a time (type I) or both bearing ISE2 permeability and rad52 double-strand-break-repair mutations the growth of which at 35 mC was dependent on C. albicans topoisomerase II, were killed by the known topoisomerase II inhibitors amsacrine and doxorubicin. Parallel experiments in yeast expressing human topoisomerase IIα allowed the relative sensitivities of the fungal and host topoisomerases to be examined in the same genetic background. To compare the killing in i o with drug inhibition in itro, the recombinant C. albicans topoisomerase II protein was expressed and purified to near-homogeneity from S. cere isiae yielding a 160 kDa polypeptide that displayed the expected ATP-dependent DNArelaxation and DNA-decatenation activities. The enzyme, whether examined in itro or complementing in S. cere isiae, was comparably sensitive to amsacrine and doxorubicin. Our results suggest that potential topoisomerase II-targeting anti-fungal inhibitors can be identified and studied in S. cere isiae.
strands (type II) [7, 8] . S. cere isiae topoisomerase I may act as a swivel during DNA replication but is dispensable for yeast growth [9] . Yeast topoisomerase II is a dimeric protein that mediates the ATP-dependent passage of one DNA duplex through a transient enzyme-bridged double-strand break in another segment [10] . Unlike human topoisomerase II, which exists in two genetically distinct isoforms, α and β [11] [12] [13] [14] , the S. cere isiae and Sch. pombe enzymes are encoded by a single-copy TOP2 gene [15, 16] . Functional topoisomerase II is essential for the growth of yeast : conditional lethal mutations in TOP2 block chromosome segregation at the non-permissive temperature [17] [18] [19] . The TOP2 genes of S. cere isiae and Sch. pombe have been sequenced and their respective 1429-and 1431-residue proteins have been overexpressed and characterized [20] [21] [22] .
Comparatively little is known about DNA topoisomerases in C. albicans. Purification of C. albicans topoisomerase I and its inhibition by aminocatechols have been reported and the corresponding TOP1 gene has been characterized [23] [24] [25] . In the case of C. albicans topoisomerase II, only one paper has appeared that describes a partial purification procedure [26] . By using this preparation in parallel with mammalian topoisomerase II, the authors identified one compound, a quinolone derivative, that preferentially inhibited the fungal enzyme. Thus selective targeting of topoisomerase II could form a basis for the discovery of fungicidal agents. To gain a better understanding of the genetics and structure of Candida topoisomerase II and to study its interactions with inhibitors, we decided to isolate the C. albicans TOP2 gene and to purify its protein product. In this paper, we describe the molecular cloning of the fungal topoisomerase II and the characterization of a recombinant enzyme overexpressed and purified from S. cere isiae. Moreover, by complementing with the fungal TOP2 gene in S. cere isiae, we have developed a yeast system for studying fungal topoisomerase inhibitors in i o. 
MATERIALS AND METHODS

Materials
Strains and plasmids
C. albicans 2402E (Hannington strain) is a clinical isolate obtained from Glaxo Wellcome, Stevenage, Herts., U.K. S. cere isiae strains JCW6 (top2-4), JN394t2-4 (MATα ISE2 ura3-52 top2-4 rad52 :: LEU2) and JEL1 (a leu2 trp1 ura3-52 prb1-1122 pep4-3 ∆his3 :: PGA10-GAL4) were kindly provided by Professor James Wang, Harvard University, Cambridge, MA, U.S.A. Plasmids YCpDEDWOB10 and YEpWOB6 were from Dr. Caroline Austin, University of Newcastle, Newcastle, U.K. Plasmid pCR was from Invitrogen, YCp50 was from New England Biolabs and pBluescript was from our laboratory collection. Supercoiled pBR322 was purified by CsCl-density ultracentrifugation as described previously [27] .
Cloning of TOP2
Genomic DNA from spheroplasts of C. albicans 2402E was isolated by standard procedures [28] . Two primers corresponding to S. cere isiae TOP2 sequence were designed to allow amplification of a C. albicans TOP2 gene fragment : forward primer 5h-TGTTGTTGGTAGAGATTATTATGG (nucleotide positions 1829-1852) and reverse primer 5h-CCATCATGATCTTGATC-GGTCATG (complementary to nucleotides 2012-2035). PCR was carried out in a 100 µl reaction sample containing 0n1 µg of genomic DNA from C. albicans 2402E (or control DNA from S. cere isiae) as template, 50 pmol of each primer, 200 µM each dNTP, 2 units of Taq polymerase and 1n5 mM MgCl # in buffer supplied by Bioline. The following temperature profile was used : 94 mC for 5 min ; then 30 cycles of 94 mC for 1 min, 48 mC for 1 min, 73 mC for 1 min ; finally, 73 mC for 5 min. S. cere isiae and C. albicans templates generated 205 and 213 bp PCR products respectively. The PCR product amplified from C. albicans was recovered by electrophoresis in 2 % low-melting-point agarose, cloned into plasmid vector pCRII and verified as TOP2 by DNA sequence analysis (see below) in comparison with that of the S. cere isiae PCR product. To identify TOP2 gene fragments by Southern-blot hybridization [29] , C. albicans 2404E DNA was digested with restriction enzymes, transferred to Hybond-N nylon membranes and cross-linked by UV irradiation. Filters were prehybridized and hybridized at 65 mC to the 213 bp C. albicans TOP2 PCR product that had been radiolabelled by random priming using [α-$#P]dCTP and the Multiprime kit (Amersham International). A single 6n3 kb C. albicans fragment hybridized to the probe ; there was no hybridization to S. cere isiae DNA. C. albicans. EcoRI fragments in the 5n5-6n5 kb size range were isolated by agarose-gel electrophoresis before ligation into pBluescript SKj and transformation of Escherichia coli DH5α. Ampicillin-resistant colonies were streaked on to Hybond-N nylon membranes placed on Luria broth-ampicillin agar plates and then grown overnight. Replica membranes were made and grown on Luria broth-agar plates for several hours until 0n5-1n0 mm-diameter colonies were obtained. The membranes were placed sequentially on Whatman 3MM paper soaked in 10 % SDS for 10 min, in 1n5 M NaCl\0n5 M NaOH for 5 min, twice for 5 min on paper soaked with 1n5 M NaCl\0n5 M TrisHCl, pH 8n0, and finally on 5iSSC (where 1iSSC is 0n15 M NaCl\0n015 M sodium citrate) for 5 min. Filters were air-dried and DNA was fixed to the membranes by UV cross-linking. The filters were probed using the same conditions as for Southernblotting except that hybridization was at 60 mC. A positive clone, pBK1, was identified that contained multiple 6 kb inserts. These EcoRI inserts were cloned individually into pBluescript SKj, and colony hybridization and DNA sequencing identified a plasmid, pBK3, that carried a 6n3 kb full-length TOP2 insert.
DNA sequence analysis
DNA was sequenced on both strands by the dideoxy-chain termination method using the Sequenase version 2n0 kit [30] . PCR products were cloned into pCRII and sequenced from T3 and T7 primers. The pBK3 insert was sequenced from both ends by using a series of primers made to accumulated sequence. Some regions of the pBK3 insert were subcloned into M13mp19 to allow single-strand sequencing of regions exhibiting compressions in the double-strand sequencing approach.
Yeast transformation and complementation
Plasmids were transformed into yeast strains using the modified lithium acetate procedure of Schiestl and Gietz [31] . For complementation studies, yeast transformants were streaked on to URA − plates and incubated for 5 days at 25 and 35 mC.
Construction of YEpWCa10
The yeast vector YEpWCa10 allowing expression of C. albicans topoisomerase II was constructed by a single-step ligation reaction involving four DNA fragments (see Figure 4) . First, the vector portion of YEpWOB6 [32] , carrying the GAL1 promoter, amp and URA genes and the replication origins for the 2 µm plasmid and pBR322, was isolated as a BamHI-XhoI fragment. A second fragment carrying BamHI and AgeI ends was made by annealing two synthetic self-complementary oligonucleotides, 5h-GATCCCGTAACCATGTCAACTGAA and 5h-CCGGTTCA-GTTGACATGGTTACGG. This fragment specifies sequence from the GAL1 promoter and the first five codons of S. cere isiae topoisomerase II. A third DNA fragment bearing sequence from codon 57 of C. albicans TOP2 and finishing at a HpaI site internal to TOP2 was obtained by PCR. The forward primer was 5h-CCTAAGCCTACACCGGTA[AAT GCT TCA GAG ACA TAT] in which the AgeI site is underlined and the sequence in brackets encodes C. albicans topoisomerase II beginning at codon 57 ; the reverse primer was 5h-CCCATTTCTACCACC-AGT corresponding to nucleotide positions 944-961, i.e. downstream of the HpaI site in the C. albicans TOP2 gene. Using pBK3 as template, and 2 units of Vent DNA polymerase at 1n5 mM MgCl # , PCR conditions were : 94 mC, 5 min ; then 30 cycles of 94 mC, 30 s ; 48 mC, 1 min ; 73 mC, 1 min ; and finally 73 mC, 5 min. The amplified PCR product was digested with AgeI and HpaI to yield a 358 bp fragment which was gel-purified. Ligation of fragments 2 and 3 through the AgeI site was expected to join the C. albicans TOP2 gene sequence to the beginning of the S. cere isiae TOP2 coding sequence. Finally, a HpaI-XhoI fragment bearing the 3h region of C. albicans TOP2 and its natural stop codon was obtained by ligating EcoRI-XhoI adaptors to the ends of the 6n3 kb EcoRI TOP2 insert isolated from pBK3 ( Figure 1 ), digesting with HpaI and XhoI and isolating the 5390 bp HpaI-XhoI TOP2 fragment. In addition to TOP2 sequence (nucleotides 551-4765), the fragment contains a partial SDHA gene ( Figure 1 ). The four fragments were combined in equimolar ratios, ligated overnight at 16 mC using T4 DNA ligase and used to transform E. coli DH5α to ampicillinresistance. Plasmids were isolated and characterized by restriction enzyme digestion. YEpWCa10 had the expected restriction map and was confirmed to be the required construct by DNA sequence analysis across the critical BamHI, AgeI and HpaI restriction sites.
Cytotoxicity assays
The drug-sensitivity of JN394 top2-4 carrying YEpWCa10 or YEpWOB6 was determined as previously described [33] . Briefly, cells were grown in minimal medium lacking uracil and supplemented with 2 % (w\v) glucose at 35 mC to late exponential phase, diluted to an A '!! of 0n4 and grown in the absence or presence of different concentrations (0-100 µg\ml) of amsacrine or doxorubicin or solvent. After 5, 10 and 24 h, cell suspensions were diluted appropriately, plated out on uracil-minus medium and grown for 5 days at 35 mC, after which the number of colonies was counted. Drug-sensitivity was plotted as percentage relative survival (cell number at 5, 10 or 24 h relative to that at time zero).
C. ablicans topoisomerase II
The enzyme was purified by a modification of the method of Worland and Wang [22] that has been developed for S. cere isiae topoisomerase II. S. cere isiae strain JEL1 transformed with YEpWCa10 was grown to late exponential phase in minimal medium lacking uracil and supplemented with 2 % (w\v) glucose, 3 % (v\v) glycerol and 2 % (w\v) lactic acid. Cells were diluted 1 : 50 in glucose-supplemented medium and grown to late exponential phase, diluted 1 : 50 into 1 litre of glucose-free medium and grown to an A '!! of 0n7. A 10 ml sample was removed and used as an uninduced control. To the remainder of the culture, 110 ml of 20 % (w\v) galactose was added, and growth was continued for another 12 h. Cells were harvested, washed with water, resuspended in buffer I (50 mM Tris\HCl, pH 7n7, 1 mM EDTA and 1 mM EDTA) containing inhibitors (1 mM PMSF, 1 mM dithiothreitol, 1 mM benzamidine, 10 µg\ml leupeptin and 10 µg\ml pepstatin A) (1 ml of buffer per g of wet packed cells), flash-frozen in liquid nitrogen and stored at k70 mC.
For enzyme preparation, all steps were carried out at 4 mC except where mentioned. Approx. 30 ml of cell suspension (from 6 litres of induced culture) were thawed on ice and distributed equally to three 30 ml round-bottomed plastic tubes (Sarstedt). An equal volume of glass beads was added and each tube was vortexed for 20 s and cooled on ice for 40 s. This procedure was repeated 15 times. Cell debris was removed by centrifugation for 15 min at 12 000 rev.\min in a Sorvall SS34 rotor. The supernatant (fraction I) was diluted to a protein concentration of 5 mg\ml with buffer I containing 25 mM KCl before the dropwise addition of 10 % (v\v) poly(ethyleneimine) (Polymin P) (pH adjusted to 7n7) to a final concentration of 0n1 %. After stirring on ice for 30 min, Celite was added (8 g per 100 ml of fraction I).
The slurry of Celite and Polymin P precipitate was poured into a column on to 4 g of prewetted Celite and allowed to settle. The column was washed with 1 column volume of buffer I containing 25 mM KCl, 3 vol. of buffer I containing 500 mM KCl, and finally 3 column volumes of buffer I containing 1 M KCl to elute the topoisomerase II activity. An equal volume of saturated (NH % ) # SO % was added to the eluate with stirring, and additional solid (NH % ) # SO % was added with stirring to 65 % saturation. After 40 min, the precipitate was pelleted by centrifugation for 25 min at 11 000 g at (12 000 rev.\min) in a Sorvall SS34 rotor. The precipitate was dissolved in buffer I (fraction II) and applied to a phosphocellulose column (1 ml volume per 5 mg of protein) equilibrated with buffer I plus 250 mM KCl. The column was washed with 1 column volume of buffer I plus 250 mM KCl and eluted with a gradient of 250 mM to 1 M KCl in buffer I. Topoisomerase II activity was eluted at about 0n5 M salt.
Recombinant S. cere isiae DNA topoisomerase II and human topoisomerase IIα were purified from S. cere isiae JEL1 strains transformed with plasmids bearing the appropriate TOP2 genes under GAL1 control as described previously [32] . The purification protocol was essentially identical with that outlined above for the C. albicans enzyme and resulted in proteins that were more than 95 % pure by SDS\PAGE analysis.
Assays of topoisomerase II
Enzyme activity was determined by the ATP-dependent relaxation of supercoiled plasmid pBR322 DNA. The standard reaction mixture contained 50 mM Tris\HCl, pH 7n4, 100 mM KCl, 10 mM MgCl # , 1 mM dithiothreitol, 0n5 mM EDTA, 1 mM ATP, 30 µg\ml BSA and 0n4 µg of supercoiled pBR322 DNA (total volume 20 µl). One unit is the amount of enzyme required to relax 50 % of the DNA in 30 min at 37 mC. Reactions were stopped by the addition of loading buffer containing 25 % glycerol, 5 % SDS and 0n25 mg\ml Bromophenol Blue and examined by electrophoresis in 0n8 % agarose gels run in TBE buffer (89 mM Tris, 89 mM boric acid and 2n5 mM EDTA). Gels were stained with ethidium bromide and photographed under UV transillumination. Decatenation assays were carried out similarly at pH 7n5, using 150 mM KCl, 50 µg\ml BSA and substituting 0n25 µg of kinetoplast DNA (from Crithidia fasciculata).
DNA cleavage
Reaction mixtures contained 50 mM Tris\HCl, pH 7n5, 100 mM KCl, 10 mM MgCl # , 0n1 mM dithiothreitol, 0n5 mM EDTA, 1 mM ATP, 5 % DMSO, 0n4 µg of supercoiled pBR322 DNA human topoisomerase IIα or recombinant C. albicans topoisomerase II, and reactions were carried out in the presence or absence of amsacrine. Samples were incubated for 30 min at 37 mC, and then further incubated with 1 µl of 10% (w\v) SDS and 1 µl of 0n5 mg\ml proteinase K for 30 min at 37 mC. Samples were analysed by electrophoresis in 0n8 % agarose.
RESULTS
Topoisomerase II encoded by C. albicans TOP2 shares closest homology with the S. cerevisiae enzyme A PCR-based approach was used to isolate a full-length C. albicans TOP2 gene. First, a 213 bp C. albicans TOP2 PCR product was amplified from C. albicans strain 2402E genomic DNA using two oligonucleotide primers made to the S. cere isiae TOP2 sequence corresponding to VVGRDYYG and MTDQDHDG motifs (residues 464-471 and 525-532) (see the Figure 1 For legend see facing page. Molecular characterization of C. albicans topoisomerase II Materials and methods section) that are also conserved in Sch. pombe topoisomerase II. When used to probe a Southern blot of 2404E DNA, the PCR product hybridized to a single " 6 kb EcoRI fragment (not shown). Plasmid clone pBK3 containing the 6n3 kb EcoRI fragment was obtained by colony hybridization using the radiolabelled PCR product to probe a size-selected library of 2402E EcoRI fragments in plasmid pBluescript (Figure  1 top) . The nucleotide sequence of the 6290 bp pBK3 insert was determined in both strands and is presented in Figure 1 bottom. Two convergent non-overlapping open reading frames were identified. An incomplete open reading frame that we designated SDHA specified a protein homologous to the C-terminal region of the flavoprotein subunit of S. cere isiae succinate dehydrogenase (Figure 1 ) [34] [35] [36] . The second open reading frame encoded a 1461-residue protein displaying close homology with the topoisomerase II proteins of S. cere isiae and Sch. pombe (Figure 2) . Homology with the known yeast topoisomerases II was greatest in the N-terminal 1-1200 residues. By analogy with the S. cere isiae enzyme [22] , the putative catalytic tyrosine of S. albicans topoisomerase II was identified as Tyr-842 (Figure 2 ). The C-terminal tail of C. albicans topoisomerase II (residues 1200-1461) was not particularly conserved and contained a number of highly acidic and highly basic tracts as well as polyserine sequences. Table 1 compares the relative sequence identities of the three yeast topoisomerases with the human topoisomerase IIα and IIβ isoforms. C. albicans topoisomerase II was most closely related to its counterpart in S. cere isiae, i.e. 55 % identity compared with 42-44 % identity with the other proteins.
Chromosome mapping of the C. albicans TOP2 and SDHA genes was carried out independently using gene-specific PCR products as probes. Both genes mapped to chromosome 4 of C.
albicans. Syngeneity does not extend to S. cere isiae, the corresponding TOP2 and SDH1 genes of which map to chromosomes XIV and XI respectively [37, 38] .
C. albicans TOP2 gene rescues growth of temperature-sensitive top2 S. cerevisiae mutants : a yeast system for studying fungal topoisomerase II inhibitors in vivo
Previous studies have elegantly shown that S. cere isiae topoisomerase II is the target in yeast for a variety of anti-cancer agents including amsacrine and etoposide [33, [39] [40] [41] . Moreover, plasmids expressing either the human TOP2α or TOP2β gene can complement a temperature-sensitive topoisomerase II mutation in S. cere isiae, allowing the effects of inhibitors to be studied against the individual α or β isoform in the same yeast background [32, 42, 43] . We noted that the inferred sequence of the fungal topoisomerase is more similar to that of its yeast counterpart than to either the human α or β isoform (Table 1 ). This observation suggested that the fungal enzyme might also complement, opening the possibility of studying anti-fungal inhibitors in the well-defined yeast system. Therefore we initially tested the putative C. albicans TOP2 gene for its ability to rescue the temperature-sensitive growth of the ura-S. cere isiae strain JCW6 conferred by the top2-4 mutation. The pBK3 insert was ligated into the shuttle vector YCp50 carrying selectable amp and URA3 genes yielding construct pBK50. Strain JCW6 was separately transformed with YCp50, pBK50 or plasmid YCpDEDWOB10 bearing the S. cere isiae TOP2 gene under the control of the constitutive S. cere isiae DED1 gene promoter [32] , and transformants were selected on uracil-minus plates. Transformants on YPDA plates were incubated for 3 days at 25 and 35 mC, the permissive and non-permissive temperatures for growth. The results are shown in Figure 3 . JCW6 and its plasmid transformants all grew at 25 mC as expected. At 35 mC, neither JCW6 nor its YCp50 transformant was able to grow, consistent with the top2-4 phenotype [32] . Plasmid YCpDEDWOB10 bearing the S. cere isiae TOP2 gene rescued growth at 35 mC as described previously [32] . Significantly, pBK50 also rescued growth at 35 mC showing that the C. albicans TOP2 gene is expressed from its own promoter and can functionally substitute for TOP2 in S. cere isiae ( Figure 3 ). However, JCW6 transformed with pBK50 grew less well than the YCpDEDWOB10 transformant, perhaps indicating that the promoter of the C. albicans TOP2 gene (or its topoisomerase II product) exhibits suboptimal activity in this yeast background.
To study the effects of topoisomerase II inhibitors in i o, it was necessary to utilize S. cere isiae strain JN394t2-4. In addition to the top2-4 mutation that blocks growth at 35 mC, the strain also has an ISE2 mutation allowing drug uptake and a rad52 repair defect that sensitizes the yeast to damage through doublestrand DNA breaks [33, 40, 41] . To examine the drug suscep- 
Figure 3 Growth of S. cerevisiae top2-4ts strain JCW6 and its TOP2 plasmid transformants at 25 mC (left) and 35 mC (middle)
Yeast strains were streaked on YPDA medium and grown for 5 days at the indicated temperatures : 1, JCW6 ; 2, JCW6 (YCp50) ; 3, JCW6 transformed with YCpDEDWOB10 carrying S. cerevisiae TOP2 gene ; 4, JCW6 transformed with pBK50, i.e. C. albicans TOP2 in YCp50.
Figure 2 Alignment of the topoisomerase II protein sequences from yeasts C. albicans (C.a.), S. cerevisiae (S.c.) and Sch. pombe (S.p.)
Asterisks and dots denote identical and conserved residues respectively. Amino acid residues are numbered on the right. Underlining indicates conserved sequences used in the design of PCR primers for isolation of the C. albicans TOP2 gene (see the text). Letters in bold denote three motifs that are highly conserved in topoisomerase II proteins. Arrowheads identify residues specified by the CUG codon, which is decoded as Ser in C. albicans and not as Leu as would be expected in the ' universal ' genetic code. The arrow indicates the catalytic tyrosine involved in enzymic DNA breakage-reunion. S. cerevisiae and Sch. pombe sequences were from refs. [20, 21] .
Figure 4 Structure and restriction map of YEpWCa10, a plasmid designed to allow overexpression of C. albicans topoisomerase II in S. cerevisiae
Sal I and Xho I sites are unique in the plasmid.
tibilities of JN394t2-4 growing at 35 mC by virtue of the C. albicans topoisomerase II in i o, we transformed the strain with plasmid YEpWCa10 in which the fungal TOP2 gene is under the control of the GAL1 promoter. YEpWCa10 allows expression of recombinant C. albicans topoisomerase II constituting residues 57-1461 fused to the first five residues of the S. cere isiae topoisomerase II (Figure 4 ). The sequence alignments in Figure Figure 
Effects of topoisomerase II-targeting agents on the viability of S. cerevisiae JN394 top2-4ts transformants growing at 3mC by virtue of human topoisomerase IIα or C. albicans topoisomerase II expressed from plasmids YEpWOB6 (right hand panels) or YEpWCa10 (left hand panels) respectively
Viable counts were determined after growth of JN394t2-4 transformants at 35 mC in the absence or presence of amsacrine (m-AMSA) (top) or doxorubicin (bottom) and are expressed as a percentage of viable counts present at time zero.
2 show that the N-terminal 56 residues of C. albicans topoisomerase II are not present in the protein from either S. cere isiae or Sch. pombe and are thus unlikely to be necessary for catalysis. YEpWCa10 is otherwise identical with plasmid YEpWOB6 which allows expression of a recombinant human α isoform in which the first 28 of the 1531 residues are replaced by the first five residues of S. cere isiae topoisomerase II. Transformation of JN394t2-4 with YEpWCa10 and YEpWOB6 facilitated direct comparison of fungal and human enzymes in i o.
Constitutive high level expression of topoisomerases II in S. cere isiae is known to inhibit growth, and so glucose was used as the carbon source in our experiments. At present, there are no commercially available inhibitors known to be selective for C. albicans topoisomerase II. Therefore to test the yeast system it was decided to use amsacrine and doxorubicin, two anti-cancer drugs known to inhibit mammalian topoisomerase II. JN394t2-4 transformants were grown in minimal medium lacking uracil at 35 mC for 5, 10 and 24 h in the absence or presence of inhibitors, and then diluted and plated on to uracil-minus plates to determine the number of viable colonies ( Figure 5 ). In the absence of drug, JN394t2-4 (YEpWCa10) grew at 35 mC giving a 10-fold increase in viable counts after 24 h ( Figure 5 left hand panels) . Inclusion of either amsacrine or doxorubicin led to time-dependent and dose-dependent reductions in viable counts. At higher drug doses, some killing was apparent after 5 h but was most marked after 24 h. For amsacrine at 10 µg\ml, there was notable reduction in viable counts and nearly three logs of killing at 100 µg\ml. Similar results were seen with doxorubicin. These experiments establish that topoisomerase II inhibitors do kill yeast cells growing by virtue of the C. albicans topoisomerase II. The right hand panels of Figure 5 show parallel experiments using JN394t2-4 (YEpWOB6) in which the drug target was human topoisomerase IIα. Dose-dependent killing of the transformants was again seen for both amsacrine and doxorubicin, and the kill curves suggest that YEpWOB6 conferred slightly greater drug sensitivity than YEpWCa10. The results in Figure 5 indicate that amsacrine and doxorubicin are inhibitors of the fungal enzyme and that such inhibitors can be studied in the yeast system.
Overexpression and purification of the recombinant fungal enzyme from S. cerevisiae : role of non-universal codons present in C. albicans TOP2
To confirm that amsacrine and doxorubicin do inhibit C. albicans topoisomerase II, it was necessary to purify the fungal protein to homogeneity to permit studies of enzyme inhibition in itro. To achieve this aim, we exploited the fact that, in YEpWCa10, the TOP2 gene is under the control of the S. cere isiae GAL1 promoter, thus allowing inducible expression in S. cere isiae on addition of galactose. The protease-deficient ura3 S. cere isiae strain JEL1 transformed with YEpWCa10 was grown in minimal medium lacking uracil and containing 3 % glycerol and 2 % lactic acid. Galactose was added to 2 % and growth was continued for 12 h. Recombinant protein was purified essentially by the method of Worland and Wang [22] using a decatenation assay to follow activity. In short, the protocol involves cell lysis, Polymin P and (NH % ) # SO % fractionation followed by chromatography on phosphocellulose. Figure 6 shows an SDS\PAGE analysis of protein fractions from a typical purification. The Coomassie-stained gel revealed a 160 kDa protein present in extracts of induced JEL1 cells containing YEpWCa10 (lane 2) that was absent from uninduced extracts (lane 1). The 160 kDa protein in peak fractions from the phosphocellulose column was more than 90 % homogeneous (lanes 3 and 4) . Approx. 300 ng of highly purified topoisomerase II could be produced per litre of yeast culture, a yield similar to that obtained for human topoisomerase IIα or β isoforms expressed using a similar approach [32, 42] .
Purified fungal topoisomerase II catalysed the relaxation of supercoiled pBR322 (Figure 7) . It was found that 6 ng of protein was sufficient to cause 50 % relaxation under standard conditions (lane 8) yielding a specific activity of 1n7i10& units\mg, a value similar to that of the purified S. cere isiae enzyme and human α and β isoforms [22, 42] . Characteristic of a eukaryotic type-II activity, relaxation was fully dependent on the inclusion of ATP (lanes 1-9) ; omission of this cofactor led to no detectable relaxation even using 600 ng of enzyme (lanes 10-18) . The results indicate that the preparation was highly active in ATP-dependent relaxation and was substantially free ( 1 %) of topoisomerase I activity.
Interestingly, when a kDNA decatenation assay was used, the specific activity of the Candida enzyme was 3i10$ units\mg, i.e. some 500-fold lower than that measured for either purified S. cere isiae topoisomerase II or the human α isoform (results not shown). One explanation for this difference could be that the native Candida enzyme is inherently less efficient in decatenation. It is also possible that the standard conditions that we used to assay and compare the decatenation activities, i.e. 1 mM ATP and 10 mM Mg# + , may not be optimal for the C. albicans protein.
Alternatively, it could be a property of the recombinant enzyme expressed in yeast. It is known that, whereas human cells and S. cere isiae utilize the universal genetic code, in C. albicans, the CUG codon is decoded as serine and not leucine as would normally be expected [44] [45] [46] . The C. albicans TOP2 gene has six CUG codons (Figure 1 ), which presumably result in Ser-to-Leu protein substitutions when expressed in S. cere isiae. Conceivably, one or more of these Ser-to-Leu substitutions present in the recombinant fungal protein could differentially affect decatenation but not relaxation activity. Whatever the effects, if any, the recombinant protein is active and complements in S. cere isiae.
Response of the fungal enzyme to topoisomerase II inhibitors that form a cleavable complex
It is known that amsacrine, doxorubicin and other topoisomerase II inhibitors form a ternary complex with enzyme and DNA (sometimes called the cleavable complex) that on addition of detergent generates permanent double-stranded breaks in DNA [39] . Formation of the cleavable complex is thought to be the lesion that underlies the cytotoxicity of many topoisomerasetargeting drugs. This feature would explain the killing by amsacrine and doxorubicin of yeast strains growing by virtue of the fungal topoisomerase II. To test this idea directly, the purified enzyme was incubated with supercoiled pBR322 DNA and ATP in the presence or absence of drug, and DNA cleavage was induced by the addition of SDS. After proteinase K treatment to remove topoisomerase II subunits covalently linked to DNA ends, DNA products were examined by agarose-gel electrophoresis (Figure 8 ). In the absence of drug, C. albicans topoisomerase II induced DNA relaxation but did not promote measurable DNA cleavage (lanes 1 and 2) . Inclusion of 10 µg\ml amsacrine stimulated DNA breakage giving approx. 50 % con- version of DNA into the linear form using 600 ng (1n8 pmol) of C. albicans enzyme (lane 3). Higher drug levels diminished cleavage and inhibited DNA relaxation (lanes 4 and 5). DNA cleavage by human topoisomerase IIα (130 ng ; 0n4 pmol) was compared in lanes 6-9. Approx. 10 % of the DNA was linearized. Allowing for differences in enzyme levels, the C. albicans and human topoisomerases were trapped with similar efficiencies by the drug. Thus these data obtained in itro are in broad agreement with the kill curves seen for the yeast transformants in Figure 5 .
DISCUSSION
Topoisomerase II of C. albicans is of considerable interest as a target for anti-fungal agents. However, little is known about the protein, and selective anti-fungal topoisomerase inhibitors have yet to be developed. To further our understanding of the fungal topoisomerase II, we have cloned and characterized the C. albicans TOP2 gene, and, by using overexpression in yeast, we have for the first time purified the recombinant enzyme to nearhomogeneity. These studies have allowed the interactions of inhibitors to be studied in itro. Moreover, we have found that the fungal TOP2 gene complements in yeast, rescuing growth of a drug-permeable S. cere isiae mutant bearing a temperaturesensitive mutation in topoisomerase II. These yeast cells, growing by virtue of the Candida enzyme, constitute a novel system for the study of fungal topoisomerase II inhibitors.
C. albicans TOP2 was cloned by a PCR method utilizing oligonucleotide primers based on S. cere isiae TOP2 sequence coding for protein motifs that are also conserved in Sch. pombe topoisomerase II (Figure 1) . The 1461-residue C. albicans topoisomerase II protein is organized in a similar fashion to other type-II topoisomerases, showing greatest identity with its counterparts in S. cere isiae and Sch. pombe, and less homology to the human α and β isoforms ( Table 1 ). The C. albicans protein had in common several motifs characteristic of topoisomerases II, namely PLRGK and MIMTDQD sequences [47] . Unexpectedly, the EGDSA motif, present in all known type-II topoisomerases described heretofore, was replaced in the Candida protein by EGLSA. This motif corresponds to a region of topoisomerase II that shares homology with the DNA gyrase GyrB protein [48] , and which in the crystal structure of an S. cere isiae topoisomerase II fragment lies above the DNA breakage-reunion domain [10] . Mutation of the GyrB EGDSA motif to EGNSA has been reported to confer resistance to quinolone anti-bacterial agents in E. coli [49] . Thus it appears that the conserved aspartate in the EGDSA structure can be replaced with other residues without complete impairment of enzyme function.
Expression of a plasmid-borne C. albicans TOP2 gene rescued the lethal phenotype of yeast top2ts mutants and also allowed purification of a functional protein product. Evidently, the fungal gene promoter is active in yeast (Figure 3) , and fungal topoisomerase II can substitute for its yeast counterpart in discharging essential functions in chromosome condensation and segregation. Complementation occurs despite the fact that the C. albicans TOP2 gene carries six CUG codons (Figure 1 ) which are read as Ser in the non-universal code used in C. albicans [44] [45] [46] but are decoded as Leu in S. cere isiae. The full-length fungal protein made in yeast therefore carries six leucine substitutions (five when expressed from YEpWCa10). With the exception of the highly conserved Ser-476, these substitutions occur at nonconserved positions. However, three residues are located in the C-terminal and N-terminal regions (Figure 2) , segments of the protein that in human and S. cere isiae topoisomerases II contain phosphorylation sites for serine\threonine kinases that appear to regulate enzyme activity (reviewed in ref. [8] ). Conceivably, these changes, or indeed the EGLSA motif, could differentially reduce decatenation activity (Figure 7 ), leaving the relaxation activity unaffected. These issues remain to be resolved.
Recombinant fungal topoisomerase II induced DNA cleavage in the presence of amsacrine and was comparably efficient with the human α isoform (Figure 8 ). These results are in agreement with previous studies using a partially purified topoisomerase II preparation from C. albicans and calf thymus topoisomerase II as a representative mammalian enzyme [26] . Differential DNA cleavage was reported for four compounds, and similar or lower levels of DNA breakage were observed for the fungal enzyme in most cases, e.g. using amsacrine or etoposide. However, a complex synthetic pentacyclic difluorinated quinolone was described, which thus far is the only reported example of an agent selective for C. albicans topoisomerase II. This situation reflects the infancy of the field, but it would appear that selective inhibitors of the fungal enzyme are there to be discovered. In itro experiments as in Figure 8 , comparing drug inhibition of highly purified C. albicans topoisomerase II and human topoisomerase isoforms, will be important in pointing up potential problems of host toxicity. Our observation that the fungal TOP2 gene rescues growth of a drug-permeable yeast top2 mutant allows the study of fungal topoisomerase II inhibitors in i o. Given that selective fungal inhibitors are not readily available, we used amsacrine and doxorubicin as model compounds to establish the point that topoisomerase II inhibitors are able to kill yeast growing by virtue of the fungal topoisomerase II ( Figure 5 ). Two lines of evidence strongly suggest that yeast killing arises from cleavable complex-formation involving the fungal protein. First, amsacrine, which induces similar levels of DNA breakage with the topoisomerases in itro, was comparably toxic to yeast cells expressing fungal or human topoisomerase II ( Figure 5 ). Secondly, etoposide, which forms cleavable complexes in itro, with mammalian topoisomerase II but much less efficiently with the recombinant fungal enzyme, killed yeast cells expressing human α but not those producing Candida topoisomerase II (results not shown). Therefore cleavable complex-formation by drugs in itro was in accord with cell killing in i o. In concert with studies on human topoisomerase isoforms expressed in the same yeast genetic background, this approach should be valuable in identifying anti-fungal inhibitors.
In summary, we have characterized for the first time the C. albicans TOP2 gene and its highly purified protein product and have established a yeast system in which cell growth depends on the expression of the fungal topoisomerase II. This system should prove useful not only in testing known and novel topoisomerase inhibitors but also, by exploiting the genetic dominance of the fungal TOP2 gene, should facilitate mutational analysis of the C. albicans topoisomerase II protein.
